Jefferies analyst Tycho Peterson lowered the firm’s price target on Danaher (DHR) to $230 from $260 and keeps a Buy rating on the shares. Danaher’s Q1 beat was “as expected,” largely on flu, but bioprocessing trends “go a long way to rebuilding credibility,” for both management and this end-market, the analyst tells investors. Given sentiment and macro headwinds, the firm thinks “shares can grind higher, with M&A optionality,” the analyst added in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Morning Movers: Danaher gains and Northrop Grumman sinks after earnings
- Danaher Receives Buy Rating from Matt Larew Amid Strong Financial Performance and Growth Potential
- Danaher reports Q1 adjusted EPS $1.88, consensus $1.64
- Danaher sees Q2 revenue up low-single digits
- Danaher sees FY25 adjusted EPS $7.60-$7.75, consensus $7.67